[go: up one dir, main page]

DK2109602T3 - Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner - Google Patents

Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner

Info

Publication number
DK2109602T3
DK2109602T3 DK07867938.8T DK07867938T DK2109602T3 DK 2109602 T3 DK2109602 T3 DK 2109602T3 DK 07867938 T DK07867938 T DK 07867938T DK 2109602 T3 DK2109602 T3 DK 2109602T3
Authority
DK
Denmark
Prior art keywords
viral
bacterial
treatment
parasitic infections
tetracycline derivatives
Prior art date
Application number
DK07867938.8T
Other languages
English (en)
Inventor
Paul Abato
Haregewein Assefa
Joel Berniac
Beena Bhatia
Todd Bowser
Laura Honeyman
Mohamed Ismail
Oak K Kim
Mark Nelson
Jingwen Pan
Atul Verma
Mark Grier
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Application granted granted Critical
Publication of DK2109602T3 publication Critical patent/DK2109602T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK07867938.8T 2006-12-21 2007-12-21 Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner DK2109602T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87631306P 2006-12-21 2006-12-21
US94300307P 2007-06-08 2007-06-08
PCT/US2007/026178 WO2008079339A2 (en) 2006-12-21 2007-12-21 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections

Publications (1)

Publication Number Publication Date
DK2109602T3 true DK2109602T3 (da) 2014-05-19

Family

ID=39495878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07867938.8T DK2109602T3 (da) 2006-12-21 2007-12-21 Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner

Country Status (16)

Country Link
US (4) US8318706B2 (da)
EP (6) EP2450347B1 (da)
JP (8) JP5583411B2 (da)
KR (1) KR101538175B1 (da)
AU (1) AU2007338747B2 (da)
BR (1) BRPI0720569B8 (da)
CA (3) CA2925939C (da)
DK (1) DK2109602T3 (da)
ES (2) ES2463457T3 (da)
HK (2) HK1135101A1 (da)
IL (4) IL270446B2 (da)
MX (1) MX2009006846A (da)
PL (1) PL2109602T3 (da)
PT (1) PT2109602E (da)
SI (1) SI2109602T1 (da)
WO (1) WO2008079339A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US7858601B2 (en) 2004-10-25 2010-12-28 Paratek Pharmaceuticals, Inc. 4-substituted tetracyclines and methods of use thereof
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
TR201818983T4 (tr) 2006-12-21 2019-01-21 Paratek Pharm Innc İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound of the pharmaceutical composition for treating a tetracycline responsive state
EA201070048A1 (ru) * 2007-07-06 2010-10-29 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
MX2010009693A (es) 2008-03-05 2010-12-20 Paratek Pharm Innc Compuestos de monociclina y metodos de uso de la misma.
JP2011517697A (ja) * 2008-04-14 2011-06-16 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
KR20110081197A (ko) * 2008-09-19 2011-07-13 파라테크 파마슈티컬스, 인크. 류마티스 관절염의 치료를 위한 테트라시클린 화합물 및 관련된 치료 방법
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
ES2654987T3 (es) * 2009-08-28 2018-02-15 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina
US8754054B2 (en) * 2010-07-09 2014-06-17 Albany Molecular Research, Inc. Antibacterial compounds, methods of making them, and uses thereof
JP6574572B2 (ja) 2011-05-12 2019-09-11 パラテック ファーマシューティカルズ インコーポレイテッド （４ｓ，４ａｓ，５ａｒ，１２ａｓ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの結晶塩及びそれを使用する方法
PL2738156T3 (pl) 2011-07-26 2018-06-29 Kbp Biosciences Usa Inc. Związki tetracyklinowe podstawione 9-aminometylem
GB2496972A (en) * 2011-11-18 2013-05-29 Redx Pharma Ltd Oxime and hydrazone derivatives of fluoroquinolone antibacterial drugs
CN103387512B (zh) * 2012-05-08 2016-08-31 成都睿智化学研究有限公司 一种米诺环素的制备方法及其中间体
EP2849757A4 (en) * 2012-05-14 2015-11-18 Paratek Pharm Innc PROCESS FOR USE OF (4S, 4AS, 5AR, 12AS -) - 4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7 - [(METHOXY (METHYL) AMINO) -METHYL] -1,11-DIOXO-1 , 4.4A, 5.5A, 6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
WO2013181391A2 (en) * 2012-05-30 2013-12-05 Paratek Pharmaceuticals, Inc. 7-disubstituted-phenyl tetracycline derivatives
US20150174144A1 (en) * 2012-07-13 2015-06-25 Paratek Pharmaceuticals, Inc. Tetracycline compounds for treating neurodegenerative disorders
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
DE102015013086A1 (de) 2015-10-01 2017-04-06 Jutta Regina Giller Attika für Gebäude
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
JP7492335B2 (ja) 2016-10-19 2024-05-29 テトラフェース ファーマシューティカルズ，インコーポレイテッド エラバサイクリンの結晶形
CA3042514A1 (en) 2016-11-01 2018-05-11 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
KR102662461B1 (ko) 2017-07-21 2024-04-30 알미랄 엘엘씨 비염증성 병변의 치료
KR102011721B1 (ko) * 2017-11-28 2019-08-19 고려대학교 산학협력단 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도
WO2019192614A1 (en) * 2018-04-06 2019-10-10 Paratek Pharmaceuticals, Inc. Process for making sarecycline hydrochloride
CN109970590A (zh) * 2018-12-20 2019-07-05 深圳市祥根生物科技有限公司 一种7-氨基米诺环素的制备方法
CN109574868B (zh) * 2018-12-28 2021-11-16 天津阿尔塔科技有限公司 一种四环素类及其差向异构体氘代内标物的制备方法
US20230181027A1 (en) * 2019-06-28 2023-06-15 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
WO2021231314A1 (en) * 2020-05-11 2021-11-18 Paratek Pharmaceuticals Inc. Methods of treating covid-19 using tetracycline compounds
CN111574392A (zh) * 2020-05-27 2020-08-25 浙江工业大学 一种6-去甲基-6-脱水四环素的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34656A (en) 1862-03-11 Improvement in liquids for exciting galvanic batteries
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) * 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3047617A (en) * 1959-05-18 1962-07-31 Pfizer & Co C Alkanoic acid esters of 5-hydroxytetracycline and process for preparation
GB921252A (en) 1960-03-09 1963-03-20 Erba Carlo Spa New tetracycline derivatives
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
GB1108310A (en) 1964-04-30 1968-04-03 Pfizer & Co C Derivatives of 6-methylene-tetracycline and process for their preparation
US3345379A (en) * 1965-02-26 1967-10-03 American Cyanamid Co 7-imidomethyl-6-demethyl-6-deoxytetracyclines
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) * 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
NL6607516A (da) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
CA999855A (en) 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
JPS5119757A (ja) 1974-06-25 1976-02-17 Farmaceutici Italia Arukirutetorasaikurinjudotainoseizoho
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US5589470A (en) * 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US4806529A (en) * 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
USRE34656E (en) * 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4806372A (en) * 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
DE4042402C1 (da) 1990-10-03 1992-09-03 Degussa Ag, 6000 Frankfurt, De
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US6756365B2 (en) * 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
DE69304292T2 (de) 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5834450A (en) 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
WO1996034852A1 (en) 1995-05-03 1996-11-07 Pfizer, Inc. Novel tetracycline derivatives
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
WO1999037307A1 (en) * 1998-01-23 1999-07-29 Trustees Of Tufts College Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6256365B1 (en) * 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
EP1240133B1 (en) 1999-09-14 2006-04-19 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
US6849615B2 (en) * 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
JP2003523963A (ja) * 2000-01-24 2003-08-12 トラスティーズ・オブ・タフツ・カレッジ クリプトスポリジウム・パルヴム関連疾患の治療のためのテトラサイクリン化合物
ATE365710T1 (de) * 2000-03-31 2007-07-15 Tufts College 7- und 9-carbamat, harnstoff, thioharnstoff, thiocarbamat und heteroaryl-amino substituierte tetracyclinverbindungen
JP2003533504A (ja) * 2000-05-15 2003-11-11 パラテック ファーマシューティカルズ インコーポレイテッド ７置換型縮合環テトラサイクリン化合物
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
AU2001268475A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) * 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US7094806B2 (en) * 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
CN1450989A (zh) * 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
ES2271070T3 (es) * 2000-07-07 2007-04-16 Trustees Of Tufts College Compuestos de minociclina 9-sustituidos.
US20050143353A1 (en) * 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
US6624168B2 (en) * 2000-07-07 2003-09-23 Trustees Of Tufts College 7,8 and 9-substituted tetracycline compounds
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1368305B1 (en) * 2001-03-13 2008-08-13 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
EP1241160A1 (en) * 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
WO2002072506A2 (en) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
EP1379255A2 (en) * 2001-03-14 2004-01-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
US7045507B2 (en) * 2001-03-14 2006-05-16 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
ES2338994T3 (es) * 2001-04-24 2010-05-14 Paratek Pharmaceuticals, Inc. Compuestos de tetraciclina sustituida para el tratamiento de la malaria.
EP2332549A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003055441A2 (en) 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
WO2003023568A2 (en) * 2001-09-10 2003-03-20 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
AU2003235759A1 (en) * 2002-01-08 2003-07-24 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EP2311451A1 (en) * 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
KR101025400B1 (ko) * 2002-03-21 2011-03-28 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
KR20050005444A (ko) 2002-04-16 2005-01-13 콜라제넥스 파마슈티칼스, 인크 안구 주사 및 적창의 동시 치료 방법
KR101148415B1 (ko) 2002-07-12 2012-05-21 파라테크 파마슈티컬스, 인크. 3, 10, 및 12ａ 치환된 테트라시클린 화합물
JP4686189B2 (ja) * 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
EP2277504A1 (en) * 2002-10-24 2011-01-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
AU2004259661B2 (en) * 2003-07-09 2011-11-10 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
EP2319828A3 (en) * 2003-07-09 2011-07-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP5010284B2 (ja) * 2004-01-15 2012-08-29 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の芳香族ａ環誘導体
WO2005082860A1 (en) * 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
CA2892332C (en) * 2004-05-21 2017-03-21 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2284153A3 (en) * 2004-10-25 2012-03-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7858601B2 (en) * 2004-10-25 2010-12-28 Paratek Pharmaceuticals, Inc. 4-substituted tetracyclines and methods of use thereof
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
AU2006272698B2 (en) * 2005-07-21 2012-11-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
EP1991236A2 (en) * 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2537934A3 (en) 2006-05-15 2013-04-10 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
IL270446B2 (en) 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound of the pharmaceutical composition for treating a tetracycline responsive state
EP2144614A1 (en) * 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
JP2010525069A (ja) 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
EA201070048A1 (ru) * 2007-07-06 2010-10-29 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
KR20110081197A (ko) * 2008-09-19 2011-07-13 파라테크 파마슈티컬스, 인크. 류마티스 관절염의 치료를 위한 테트라시클린 화합물 및 관련된 치료 방법

Also Published As

Publication number Publication date
EP2109602A2 (en) 2009-10-21
IL234755A (en) 2017-03-30
CA2673466A1 (en) 2008-07-03
JP2014167027A (ja) 2014-09-11
JP2021063137A (ja) 2021-04-22
EP2452935A3 (en) 2012-08-29
EP2452935A2 (en) 2012-05-16
EP2109602B1 (en) 2014-02-12
JP2024009235A (ja) 2024-01-19
IL302749A (en) 2023-07-01
EP2450347A1 (en) 2012-05-09
EP2455367B1 (en) 2015-12-16
EP3812372A2 (en) 2021-04-28
PT2109602E (pt) 2014-05-23
SI2109602T1 (sl) 2014-06-30
BRPI0720569B8 (pt) 2021-05-25
US8318706B2 (en) 2012-11-27
US20130102779A1 (en) 2013-04-25
EP2450347B1 (en) 2015-06-24
US20100305072A1 (en) 2010-12-02
BRPI0720569A2 (pt) 2014-02-04
PL2109602T3 (pl) 2014-09-30
KR101538175B1 (ko) 2015-07-20
WO2008079339A3 (en) 2008-12-18
IL270446B1 (en) 2023-06-01
HK1170218A1 (en) 2013-02-22
JP2015205939A (ja) 2015-11-19
IL250858B (en) 2019-11-28
WO2008079339A2 (en) 2008-07-03
HK1135101A1 (en) 2010-05-28
JP6061897B2 (ja) 2017-01-18
JP2018039846A (ja) 2018-03-15
ES2463457T3 (es) 2014-05-28
CA3051994A1 (en) 2008-07-03
CA2925939C (en) 2019-10-01
JP2010513527A (ja) 2010-04-30
CA2673466C (en) 2016-06-14
KR20090098986A (ko) 2009-09-18
BRPI0720569B1 (pt) 2020-10-13
IL270446B2 (en) 2023-10-01
ES2548261T3 (es) 2015-10-15
EP2455367A1 (en) 2012-05-23
MX2009006846A (es) 2009-08-20
JP5583411B2 (ja) 2014-09-03
US9012433B2 (en) 2015-04-21
JP2019081802A (ja) 2019-05-30
EP3812372A3 (en) 2021-06-30
US20210395189A1 (en) 2021-12-23
AU2007338747B2 (en) 2013-12-19
CA2925939A1 (en) 2008-07-03
AU2007338747A1 (en) 2008-07-03
IL270446A (da) 2019-12-31
US20160046561A1 (en) 2016-02-18
IL250858A0 (en) 2017-04-30
EP3045449A1 (en) 2016-07-20
JP2011093914A (ja) 2011-05-12

Similar Documents

Publication Publication Date Title
DK2109602T3 (da) Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner
DK2227213T3 (da) Sammensætninger og fremgangsmåder til behandling af vaginale infektioner og patogene, vaginle biofilm
DK2181330T3 (da) Sammensætninger og midler til diagnosticering af mikrobielle infektioner
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK2057153T3 (da) (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
DK1765288T3 (da) Tobramycinpræparater til behandling af endobronchiale infektioner
BRPI0816116A2 (pt) Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
DK1755661T3 (da) Gelsolin til anvendelse til behandling af infektioner
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
EP4125244C0 (en) HASH BASED MULTIHOSTING
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
DK1931350T3 (da) Administration af inhibitorer af dipeptidylpeptidase
DK1945277T3 (da) Opretholdelse af desinfektion af medicinsk udstyr
EP1882441A4 (en) ENDOSCOPE SYSTEM, CONTROL PROGRAM FOR ENDOSCOPE SYSTEM, AND CONTROL METHOD FOR ENDOSCOPE SYSTEM
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
IL195272A0 (en) Methods and compositions for the treatment of viral infections
DK1957050T3 (da) Polypeptidfilm og fremgangsmåder
DK1902050T3 (da) Oxazolidinonderivater og anvendelse deraf som antibiotika
DK2022735T3 (da) Overføringsapparat og overføringsgenstands-inspektionsapparat
SG131822A1 (en) Treating avian influenza infections
EP1982145A4 (en) ALIGNMENT CORRECTION SYSTEM AND METHODS OF USE
EP2020857A4 (en) ANTIMICROBIAL THERAPY OF BACTERIAL INFECTIONS
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
DK2022504T3 (da) Salve til behandling af hæmorider